Source Google Doc: see frontmatter source_artifacts. Original title: "THE PROTEIN ECONOMY".

The Thesis (One Sentence)

"Protein consumption is transitioning from a fitness niche to a universal dietary imperative — driven by GLP-1 muscle-loss anxiety, social media 'protein-maxxing' culture, and aging demographics — and the pure-play beneficiary, BellRing Brands (BRBR), is trading at a 70%+ discount to fair value estimates while Wall Street obsesses over transient whey costs."

Why This Is a Perfect Example of All Three Paradigms

Paradigm 1 (Supply Chain): Traces from GLP-1 drugs → muscle loss side effect → protein demand → specific protein brands → BRBR as pure-play.

Paradigm 2 (Picks-and-Shovels): "The crowd is buying Eli Lilly and Novo Nordisk. This is how we invest in the DOWNSTREAM effects." BRBR is the picks-and-shovels of GLP-1 — they don't make the drug, they make what every drug user NEEDS.

Paradigm 3 (Cultural Arbitrage): "Classic Camillo gap: cultural truth vs. Wall Street narrative." Social media flooded with protein-maxxing content. 86% of Americans actively adding protein. Starbucks selling Protein Lattes. Wall Street focused on whey costs (cyclical noise), missing the secular demand signal.

Key Data Points

The Three Signals

1. Protein-Maxxing = Dominant Food Trend 2026 — 78% of US consumers tracking protein. RTD protein shakes growing 7.4%. Bars 6.8%. Starbucks Protein Lattes = mainstream arrival.

2. GLP-1 Muscle Loss Feedback Loop — "Up to 40% of weight lost on semaglutide comes from lean mass (muscle), not fat." Every GLP-1 patient is told to eat more protein. Creates medically-mandated demand loop. Oral GLP-1 pills in 2026 will dramatically expand adoption.

3. Demographic Breadth — Not just gym bros. 83% of Boomers say protein goals are important. Millennials have the widest "protein gap." GLP-1 users skew older = high disposable income.

What This Means for Our Research

Our GLP-1 blind test is ANSWERED

We had "GLP-1 drug manufacturing bottleneck" as a Priority 1 blind test thesis. Revan answered a DIFFERENT version — not "who makes the drug" but "who benefits from the drug's SIDE EFFECTS." That's a more creative thesis. Our agents would likely trace the peptide manufacturing chain (Bachem, etc.) but Revan traced the CULTURAL cascade (drug → muscle loss fear → protein demand → BRBR).

BRBR is not in any of our watchlists

• Down 78% from peak
• Analyst target 169% above current
• This is the kind of name our bargain-bin scan SHOULD catch (extreme drawdown on quality company) but doesn't because it's not in any watchlist
• Need to add to consumer or a dedicated "cultural-thesis" watchlist

The "Camillo gap" framework

Revan explicitly uses Camillo's framework: "cultural truth vs. Wall Street narrative." The protein trend is visible on TikTok, Reddit, and in every grocery store. Wall Street sees whey cost inflation. The gap between what CONSUMERS are doing and what ANALYSTS are modeling is the investment edge.

This validates our three-paradigm framework

One conviction doc uses ALL THREE paradigms simultaneously:

• Supply chain (GLP-1 → side effects → protein demand → BRBR)
• Picks-and-shovels (don't buy LLY/NVO, buy what their patients NEED)
• Cultural arbitrage (TikTok protein-maxxing, Starbucks Protein Lattes, 86% survey data)

New Tickers / Leads